Abbott (NYSE:ABT) said today its Tecnis Symfony 1-piece acrylic intraocular lens met its primary endpoint in the pivotal trial of the device designed for cataract surgery.
Data from the trial indicated that people who were implanted with the lens demonstrated improved intermediate and near vision compared to those who received a monofocal intraocular lens, the company said.
Results from the trial were presented at a meeting of the American Society of Cateract and Refractive Surgery in New Orleans this week.
“Many people with cataracts are asking for an option that will help them perform near activities like reading, use their computers and tablets at intermediate distance, as well as see objects that are far away. The data from this study showed that patients who received the Symfony lens were more likely to achieve improved intermediate and near vision, while maintaining similar distance vision compared with patients who received a standard IOL,” study investigator Dr. Jason Jones of Sioux City, Iowa’s Jones Eye Clinic said in a press release.
The company said its Tecnis Symfony IOL is designed to elongate the range of focus of the eye and provide a continuous range of vision at near, intermediate and long distances.
“Today, people with cataracts want the ability to choose a lens that is likely to give them the vision they want so they can continue to be active and lead fulfilling lives. The existing Tecnis family of IOLs offers personalized options for patients. The Symfony data presented at ASCRS will be used to support our regulatory application for the lens in the U.S., potentially providing even more choices to doctors and patients,” vision biz prez Thomas Frinzi said in prepared remarks.
Data from the 298-patient multicenter, prospective, randomized trial indicated that patients treated with the Tecnis Symfony reported 1.7 more lines on the uncorrected intermediate visual acuity test and and 2.4 more lines on the distance corrected intermediate visual acuity at 66cm than those treated with a monofocal IOL at 6 months.
Symfony IOL patients achieved average binocular intermediate visual acuity of 20/20, the company reported, with rates of adverse events similar between groups.
Data from a separate 735-patient trial was also presented, with results indicating that the Symfony lens was associated with low levels of glare, halo and starburst, with a 91% rate patient satisfaction, the company said.
